Class/mechanism: Competitive direct thrombin inhibitor. Inhibition of thrombin, a serine protease, inhibits the conversion of fibrinogen into fibrin in the coagulation cascade and subsequent development of thrombus. Dabigatran inhibits free thrombin, clot-bound thrombin, and thrombin-induced platelet aggregation.
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.
Idarucizumab (Praxbind) can rapidly and completely reverse the effects of dabigatran as measured by normalization of dilute thrombin time.
Diseases for which it is used
- Atrial fibrillation
- Venous thromboembolism
Patient drug information
History of changes in EMA indication
- 2008-03-17: Initial authorization
Also known as
- Brand names: Pradax, Pradaxa, Prazaxa